Patents by Inventor Steven K. Dower

Steven K. Dower has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Type I IL-1 receptors
    Publication number: 20040101528
    Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.
    Type: Application
    Filed: December 3, 2002
    Publication date: May 27, 2004
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Type II IL-1 receptors
    Publication number: 20030060616
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Application
    Filed: July 19, 2002
    Publication date: March 27, 2003
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Type II Interleukin-1 receptors
    Patent number: 6521740
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Antibodies to interleukin-1 receptors
    Patent number: 6511665
    Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 28, 2003
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • DNA encoding type II IL-1 receptors
    Patent number: 6504023
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: January 7, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Soluble type II interleukin-1 receptors and methods
    Patent number: 5767064
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed. Also disclosed are compositions and methods for regulating an IL-1 mediated immune or inflammatory response in a mammal.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: June 16, 1998
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Cytokine that binds ST2
    Patent number: 5576191
    Abstract: ST2 ligand polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing ST2 ligand polypeptides. The ST2 ligand polypeptide binds to a receptor that is expressed on cell types that include certain Hodgkin's Disease-derived tumor cells.
    Type: Grant
    Filed: June 17, 1994
    Date of Patent: November 19, 1996
    Assignee: Immunex Corporation
    Inventors: Margit Gayle, Jennifer L. Slack, Hans-Juergen Gruss, John E. Sims, Steven K. Dower
  • Method of using soluble human interleukin-1 receptors to suppress immune responses
    Patent number: 5492888
    Abstract: Methods of using shuIL-1Rs to suppress IL-1 mediated immune responses in a mammal.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: February 20, 1996
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Method of using soluble human interleukin-1 receptors to suppress inflammation
    Patent number: 5488032
    Abstract: Methods of using shulL-1Rs to suppress IL-1 mediated inflammation in a mammal.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: January 30, 1996
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Type II Interleukin-1 receptors
    Patent number: 5464937
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: November 7, 1995
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • DNA encoding type II interleukin-1 receptors
    Patent number: 5350683
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: July 12, 1993
    Date of Patent: September 27, 1994
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Soluble interleukin-1 receptors
    Patent number: 5319071
    Abstract: Substantially purified and homogeneous soluble human interleukin-1 receptor (shuIL-1R) proteins, DNA encoding the shuIL-1R proteins and pharmaceutical compositions containing the shuIL-1R proteins are described.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: June 7, 1994
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John Sims, David L. Urdal
  • Purification of the IL-2 receptor
    Patent number: 5317087
    Abstract: Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromatography in conjunction with a monoclonal antibody directed to the receptor. The purification process also includes reversed phased high performance liquid chromatography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has made possible the sequencing of the amino acid residues at the N-terminal of this protein molecule. Double-stranded cDNA is prepared from polyadenylated RNA extracted from cell lines or other sources known to produce IL-2 receptor. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools.
    Type: Grant
    Filed: October 22, 1990
    Date of Patent: May 31, 1994
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Cosman, Steven K. Dower, Carl J. March, David L. Urdal, Alf D. Larsen
  • Process for purifying interleukin-1 receptors
    Patent number: 5296592
    Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: March 22, 1994
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Soluble human interleukin-1 receptors, compositions and method of use
    Patent number: 5180812
    Abstract: Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.
    Type: Grant
    Filed: December 21, 1989
    Date of Patent: January 19, 1993
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Interleukin-1 receptors
    Patent number: 5081228
    Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: October 13, 1988
    Date of Patent: January 14, 1992
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Interleukin-1 receptors
    Patent number: 4968607
    Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: February 25, 1988
    Date of Patent: November 6, 1990
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
  • Hybridoma antibody which binds IL-2 receptor
    Patent number: 4845198
    Abstract: A monoclonal antibody which specifically binds to the human IL-2 receptor, and a hybridoma which produces the antibody, are disclosed.
    Type: Grant
    Filed: December 17, 1986
    Date of Patent: July 4, 1989
    Assignee: Immunex Corporation
    Inventors: David L. Urdal, Carl J. March, Steven K. Dower
  • Interleukin 2 receptor
    Patent number: 4578335
    Abstract: Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromotography in conjunction with a monoclonal antibody directed to the receptor. Purification also involved reversed phased high performance liquid chromotography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has enabled this protein molecule to be partially sequenced.
    Type: Grant
    Filed: May 21, 1984
    Date of Patent: March 25, 1986
    Assignee: Immunex Corporation
    Inventors: David L. Urdal, Carl J. March, Steven K. Dower
  • Soluble human interleukin-1 receptors, compositions and method of use
    Patent number: RE35450
    Abstract: Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: February 11, 1997
    Assignee: Immunex Corporation
    Inventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal